WISSENSCHAFTLICHE ARBEITEN

Diplomarbeit 

 

Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program?

Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University of Vienna

 

Betreute Diplomarbeiten 

 

2015

- Prognostic significance of thyroid hormones in patients with hepatocellular carcinoma -  Haupt Lukas

Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University of Vienna
- Influence of portal hypertension on prognosis of patients with hepatocellular carcinoma - Eva Pachta
Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University of Vienna

- Prognostic significance of platelets in patients with hepatocellular carcinoma Sabine Popp

Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University of Vienna

- Prognostic significance of HAP-, STATE-, and ART-score in patients with HCC on the waiting list for liver transplantation Carina Gabler

Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University of Vienna

 

2021

- Bacterial spectrum and antibiotic resistance in patients with spontaneous bacterial peritonitis in Southern Austria -  Fabian Johannes Gesierich

Department of Gastroenterology & Hepatology, Endocrinology, Rheumatology and Nephrology, Klinikum Klagenfurt am Wörthersee

 

- Retrospective analysis of prognostic factors and therapy modalities in patients with primary liver cancer  - Anna Knaus

Department of Gastroenterology & Hepatology, Endocrinology, Rheumatology and Nephrology, Klinikum Klagenfurt am Wörthersee

 

- Retrospective analysis of the risk of gastrointestinal bleeding associated with non-vitamin K oral anticoagulants compared to vitamin K oral anticoagulants - Iris Spatschil

Department of Gastroenterology & Hepatology, Endocrinology, Rheumatology and Nephrology, Klinikum Klagenfurt am Wörthersee

 

2023

- Epidemiologic trends in HCC patients in Carinthia - Heleen Emmer

Department of Gastroenterology & Hepatology, Endocrinology, Rheumatology and Nephrology, Klinikum Klagenfurt am Wörthersee

 

 

 

Erstautorenschaften

 

1. Hucke F, Sieghart W, Schoeniger-Hekele M, Peck-Radosavljevic M, Muller C.

Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

Wiener klinische Wochenschrift 2011; 123(17-18): 542-51.

 

 2. Sieghart W*, Hucke F*, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H, Trauner M, Peck-Radosavljevic M.

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.

Hepatology 2013; 57(6): 2261-73. *contributed equally

 

3. Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W.

How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.

Journal of hepatology 2014; 61(6): 1287-96.

 

4. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M.

The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.

Journal of hepatology 2014; 60(1): 118-26.

 

5. Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-Radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria    2010–2018. Cancers. 2022; 14(13):3093. https://doi.org/10.3390/cancers14133093

 

6. Hucke F, Emmer H, Emmer R, Hucke M, Bota S, Fürstner M, Hausegger K, Mittermair R, Peck-Radosavljevic M. Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012-2023. Cancers. 2023; 15, 5215. https://doi.org/10.3390/cancers15215215

 

 

Co-autorenschaften

 

 1. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grunberger B, Schoniger-Hekele M, Muller C, Peck-Radosavljevic M.

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.

Aliment Pharmacol Ther 2011; 34(8): 949-59.

 

2. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Konigsberg R, Stauber R, Grunberger B, Muller C, Kolblinger C, Peck-Radosavljevic M, Sieghart W.

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Radiology 2012; 263(2): 590-9.

 

3. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, Vogel W, Trauner M, Peck-Radosavljevic M.

Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.

Hepatology 2013; 57(6): 2224-34.

 

4. Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M. Epidemiological trends of hepatocellular carcinoma in Austria.

Dig Dis 2014; 32(6): 664-9.

 

5. Pinter M, Hucke F, Zielonke N, Waldhor T, Trauner M, Peck-Radosavljevic M, Sieghart W.

Incidence and mortality trends for biliary tract cancers in Austria.

Liver international 2014; 34(7): 1102-8.

 

 6. Sieghart W, Hucke F, Peck-Radosavljevic M.

Transarterial chemoembolization: modalities, indication, and patient selection.

Journal of hepatology 2015; 62(5): 1187-95.

 

7. Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, Sieghart W.

The impact of thyroid hormones on patients with hepatocellular carcinoma. PloS one 2017; 12(8): e0181878.

 

8. Pinter M, Weinmann A, Worns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

United European Gastroenterol J 2017; 5(7): 987-96.

 

9. Wengert GJ, Baltzer PAT, Bickel H, Thurner P, Breitenseher J, Lazar M, Pones M, Peck-Radosavljevic M, Hucke F, Ba-Ssalamah A.

Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging.

Acad Radiol 2017; 24(12): 1491-500.

 

10. Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Muller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Liver Cancer 2019; 8(3): 203-17.

 

11. Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Muller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Aliment Pharmacol Ther 2019; 49(10): 1323-33.

 

12. Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, Garcia-Finana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ.

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.

Hepatology 2020; 72(1): 198-212.

 

13. Peck-Radosavljevic M, Bota S, Hucke F.

Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?-the SCOOP-2 trial experience.

Ann Transl Med 2020; 8(21): 1340. - Editorial

 

14. Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Muller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rossler F, Siebenhuner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Muller-Stich B, Kikuchi H, Duda DG, Kutting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Nature 2021. Apr;592(7854):450-456.

 

15. Bota S., Razpotnik M. , Hucke F., Urak  C. , Flatscher K., Peck-Radosavljevic M.

Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.

Wien Klin Wochenschr. 2021 Jul;133(13-14):641-646

 

16. Scheiner B., Pomej K., Kirstein MM., Hucke F., Finkelmeier F., Waidmann O., Himmelsbach V., Schulze K., von Felden J., Fründt TW., Stadler M., Heinzl H., Shmanko K., Spahn S., Radu P., Siebenhüner AR., Mertens JC., Rahbari NN., Kütting F., Waldschmidt DT., Ebert MP., Teufel A., De Dosso S., Pinato DJ., Pressiani T., Meischl T., Balcar L., Müller C., Mandorfer M., Reiberger T., Trauner M., Personeni N., Rimassa L., Bitzer M., Trojan J., Weinmann A., Wege H., Dufour JF., Peck-Radosavljevic M., Vogel A., Pinter M.

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

J Hepatol. 2022 Feb;76(2):353-363.

 

17. Purevsambuu T., Bota S., Hucke F., Hofer H., Ferenci P., Sieghart W., Peck- Radosavljevic M.

Hepatocellular Carcinoma incidence in Chronic Hepatitis C patients according to Sustained Virologic Response (SVR) with Interferon-based therapies and baseline characteristics

Liver Cancer International. 2022 – https://doi.org/10.1002/lci2.52

 

18. Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, Fründt TW, von Felden J, Schulze K, Himmelsbach V, Finkelmeier F, Deibel A, Siebenhüner AR, Shmanko K, Radu P, Schwacha-Eipper B, Ebert MP, Teufel A, Djanani A, Hucke F, Balcar L, Philipp AB, Hsiehchen D, Venerito M, Sinner F, Trauner M, D'Alessio A, Fulgenzi CAM, Pinato DJ, Peck-Radosavljevic M, Dufour JF, Weinmann A, Kremer AE, Singal AG, De Toni EN, Rimassa L, Pinter M.

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.

JHEP Rep. 2022 Oct 27;5(1):100620.

 

 

Präsentationen und Preise bei /von Kongressen

 

2011

·         ÖGGH annual conference Salzburg, Poster presentation

2013

·         ÖGGH annual winter meeting Galtür, Oral presentation

·         ÖGGH annual meeting Graz, Oral presentation and best oral presentation price

·         ÖGIM annual meeting Salzburg, Poster presentation and best poster price

 

2014

·         EASL International liver congress London, Oral presentation

·         ÖGGH annual meeting Villach, Ferring price

2015

·         EASL international liver congress Vienna, Oral presentation

2020

·         ÖGGH annual meeting virtual – oral presentation